Mortality in treated heterozygous familial hypercholesterolaemia: Implications for clinical management

Atherosclerosis

Volumn 142, Issue 1, 1999, Pages 105-112

  Neil, H A W ^a   Betteridge, D J ^a   Broome, K ^a   Durrington, P N ^a   Hawkins, M M ^a   Humphries, S E ^a   Mann, J I ^a   Miller, J P ^a   Thompson, G R ^a   Thorogood, M ^a   Potok, M ^a   Mathews, F ^a   Arnsten, K ^a   Flemming, S ^a   Alkeles, R S ^a   Finnie, R M ^a   Galton, D J ^a   Hillson, R ^a   Hughes, E A ^a   Laker, M F ^a   Lewis, B ^a   Wierzbicki, A S ^a   Lorimer, R ^a   Matthews, D R ^a   Reckless, J P D ^a   Sandle, L N ^a   Seed, M ^a   Taylor, K G ^a   West, R ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Coronary heart disease; Familial hypercholesterolaemia; Mortality

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CORONARY RISK; DRUG EFFICACY; FEMALE; FOLLOW UP; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032890205     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00200-7     Document Type: Article

References (33)

1. Goldstein J.L., Brown M.S. Familial hypercholesterolaemia. Stanbury J.B., Wyngaarden J.B., Fredrickson D.S., Goldstein J.L., Brown M.S. The metabolic basis of inherited disease. 5th edn. 1983;672-712 McGraw-Hill, New York.
2. Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. B Med J 1991;303:893-6.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
4. Shepherd J., Cobbe S.M., Ford I., Isles C., Lorimer A.R., MacFarlane P.W. et al. Prevention of coronary heart disease in men with hypercholesterolaemia. New Engl J Med. 333:1995;1301-1307.
5. Newman T.B., Hulley S.B. Carcinogenicity of lipid-lowering drugs. J Am Med Assoc. 275:1996;55-60.
6. Jackson R. Evidence-based management of dyslipidaemia. Lancet. 346:1995;1440-1441.
7. Ramsey L.E., Haq I.U., Jackson P.R., Yeo W.W. The Sheffield table for primary prevention of coronary disease: corrected. Lancet. 348:1996;1251-1252.
8. Anderson K.M., Odell P.M., Wilson P.W.F., Kannel W.B. Cardiovascular disease risk profiles. Am Heart J. 121:1990;293-298.
9. Friedewald W.T., Levy R.I., Fredickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
10. Coleman M., Douglas A., Hermon C., Peto J. Cohort study analysis with a Fortran computer program. Int J Epidemiol. 15:1986;134-137.
11. Breslow N.E., Day N.E. The design and analysis of cohort studies. Statistical analysis in cancer research. 2:1988;69 Oxford University Press, Oxford.
12. Jensen J., Blackenhorn D.H., Kornerup V. Coronary disease in familial hypercholesterolaemia. Circulation. 36:1976;77-82.
13. Manolio T.A., Pearson T.A., Wenger N.K., Barrett-Connor E., Payne G.H., Harlan W.R. Cholesterol and heart disease in older persons and women: review of an NHLBI workshop. Ann Epidemiol. 2:1992;155-160.
14. Stamler J., Wentworth D., Neaton S.D. Is relationship between cholesterol and risk of premature death from coronary heart disease continuous and graded? J Am Med Assoc. 256:1986;2823-2828.
15. Heiberg A., Slack J. Family similarities in the age at coronary death in familial hypercholesterolaemia. B Med J. 2:1977;493-495.
16. Vohl M.C., Gaudet D., Moorjani S., Tremblay G., Perron P., Gagne C. et al. Comparison of the effect of two low-density lipoprotein receptor class mutations on coronary heart disease among French-Canadian patients heterozygous for familial hypercholesterolaemia. Eur J Clin Invest. 27:1997;366-373.
17. Jeenah M., September W., van Roggen F.G., de Villiers W., Seftel H., Marais D. Influence of specific mutations at the LDL receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia. Atherosclerosis. 98:1993;51-58.
18. Thompson G.R., Seed M., Niththyananthan S., McCarthy S., Thorogood M. Genotypic and phenotypic variation in familial hypercholesterolaemia. Atherosclerosis. 9(suppl 1):1989;75-80.
19. Eto M., Watanabe M., Chonan H., Ishii K. Familial hypercholesterolaemia and apolipoprotein E4. Atherosclerosis. 72:1988;123-128.
20. Seed M., Hoppichler F., Reaveley D., McCarthy S., Thompson G.R., Boerwinkle E. et al. Relation of serum lipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolaemia. New Engl J Med. 322:1990;1494-1499.
21. Miettinen T.A., Gylling H. Mortality and cholesterol metabolism in familial hypercholesterolaemia. Atherosclerosis. 8:1988;163-167.
22. Hill J.S., Hayden M.R., Frohlich J., Pritchard P.H. Genetic and environmental factors affecting the incidence of coronary heart disease in heterozygous familial hypercholesterolaemia. Atheroscler Thromb. 11:1991;290-297.
23. Beaumont V.B., Jacotot B., Beaumont J.-L. Ischaemic disease in men and women with familial hpercholesterolaemia and xanthomatosis. Atherosclerosis. 24:1976;441-450.
24. Streja D., Steiner G., Kwiterovich P.O. Plasma high-density lipoproteins and ischemic heart disease. Ann Intern Med. 89:1978;871-880.
25. Moorjani S., Gagne C., Lupien P.J., Brun D. Plasma triglyceride-related disease in high-density lipoprotein cholesterol and its association with myocardial infarction in heterozygous familial hypercholesterolaemia. Metabolism. 35:1986;311-316.
26. Colhoun H, Prescott-Clarke P, editors. Health Survey for England 1994, Vol. 1: Findings. London: HMSO, 1996.
27. Sacks F.M., Peffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl Med J. 335:1996;1001-1009.
28. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J Am Med Assoc 1984;251:365-74.
29. Durrington P.N. Normal lipid and lipoprotein levels in childhood and adolescence. Neil A., Rees A., Taylor C. Hyperlipidaemia in childhood. 1996;9-16 Royal College of Physicians of London, London.
30. Volmink J.A., Newton J., Hicks N., Sleight P., Fowler G.H., Neil H.A.W. Coronary event and case fatality rates in an English population: results of the Oxford Myocardial Infaction Incidence Study. Heart. 79:1998;40-44.
31. Slack J. Risks of ischaemic heart disease in familial hyperlipidaemic states. Lancet. ii:1969;1380-1382.
32. Stone N.J., Levy R.I., Fredrickson D.S., Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinaemia. Circulation. 49:1974;476-488.
33. Durrington P.N. Familial hypercholesterolaemia, Ch. 5. Hyperlipidaemia, diagnosis and management. 2nd edition:1995;108-139 Butterworth Heinemann, London.